There is considerable interest in the use of bioorthogonal covalent chemistry, such as "click" reactions, to label small molecules located on live or fixed cells.
Neal K. Devaraj, Rabi Upadhyay, Jered B. Haun, Scott A. Hilderbrand,* and Ralph Weissleder* There is considerable interest in the use of bioorthogonal covalent chemistry, such as "click" reactions, to label small molecules located on live or fixed cells. [1] Such labeling has been used for the visualization of glycans, activity-based protein profiling, the site-specific tagging of proteins, the detection of DNA and RNA synthesis, investigation of the fate of small molecules in plants, and the detection of posttranslational modification in proteins. [2] [3] [4] Most reported applications rely on either the copper-catalyzed azide-alkyne cycloaddition, which is limited to in vitro application owing to the cytotoxicity of copper, or the elegant strain-promoted azide-alkyne cycloaddition, which is suitable for live-cell and in vivo application but is hindered by relatively slow kinetics and the often difficult synthesis of cyclooctyne derivatives. [4, 5] New bioorthogonal reactions that do not require a catalyst and show rapid kinetics are therefore of interest for different molecular-imaging applications at the cellular level. Herein we demonstrate the use of an inverse-electron-demand DielsAlder cycloaddition between a serum-stable 1,2,4,5-tetrazine and a highly strained trans-cyclooctene to covalently label live cells. We applied this reaction to the pretargeted labeling of epidermal growth factor receptor (EGFR) tagged with cetuximab (Erbitux) on A549 cancer cells. We found that the tetrazine cycloaddition to trans-cyclooctene-labeled cells is fast and can be amplified by increasing the loading of the dienophile on the antibody. This highly sensitive targeting strategy can be used to label proteins by treatment with a secondary agent at nanomolar concentrations for short durations of time.
Recently, we and others explored strain-promoted inverse-electron-demand Diels-Alder cycloaddition reactions of 1,2,4,5-tetrazines for bioconjugation. [6, 7] We showed that the cycloaddition of a tetrazine with a norbornene can be applied to the pretargeted imaging of live breast cancer cells. However, the rate of cycloaddition of the tetrazine with norbornene was 1.6 m À1 s À1 in serum at 20 8C. This rate is comparable to previously reported rates for optimized azidecyclooctyne cycloaddition reactions and requires micromolar concentrations for sufficient labeling. [3, 4] On the basis of previously reported rate constants, we decided to investigate the coupling of tetrazines with more-strained dienophiles. [8] Higher rate constants would enable faster and more efficient labeling. Thus, less of the labeling agent would be required, and the background signal would be decreased.
Fox and co-workers recently reported the use of a highly strained trans-cyclooctene for bioconjugation. [6, 9] Although the rates reported were impressive, the tetrazine that yielded the fastest rate has limited stability to nucleophiles and aqueous media, with significant degradation observed after several hours. In contrast, we reported the use of the novel asymmetric tetrazine 1, which is very stable in water as well as in whole serum: a prerequisite for in vivo applications. [7] We hypothesized that tetrazine 1 would react with trans-cyclooctene significantly faster than the previously reported norbornene and this would greatly improve the sensitivity of cell labeling by tetrazine cycloaddition.
With this goal in mind, we synthesized the trans-cyclooctene dienophile 2 in two steps from a commercially available cyclooctene epoxide. The trans-cyclooctene reacted readily with tetrazine 1 to form isomeric dihydropyrazine conjugation products in greater than 95 % yield ( Figure 1 a; see also the Supporting Information). The trans-cyclooctenol 2 can be converted into the reactive succinimidyl carbonate, and the carbonate can be conjugated to amine-containing biomolecules, such as monoclonal antibodies, through the formation of a carbamate linkage. To determine the secondorder rate constant for the reaction of the tetrazine with the trans-cyclooctene, we modified surface arrays of trans-cyclooctene-functionalized antibodies with a fluorescent tetrazine probe and monitored the fluorescence signal over time (see Figure S3a in the Supporting Information). From these data, we determined a second-order rate constant of 6000 AE 200 m À1 s À1 at 37 8C (see Figure S3b in the Supporting Information). This rate constant is several orders of magnitude higher than the previously reported value for the cycloaddition of tetrazine 1 with a norbornene derivative, as well as the previously reported rate constants for bioorthogonal click reactions used to label live cells covalently. [3, 4, 7] To demonstrate the utility of the reaction of a tetrazine with a trans-cyclooctene for live-cell imaging, we chose to label EGFR expressed on A549 lung cancer cells with the anti-EGFR monoclonal antibody cetuximab. The concept of pretargeting is illustrated in Figure 1 b. The multistep labeling of monoclonal antibodies is of interest as a result of the long blood half-life of antibodies. This property leads to poor target-to-background ratios when the antibodies are labeled directly with imaging agents or cytotoxins. [10] A small-molecule-based pretargeting strategy that relies on irreversible covalent chemistry may circumvent these problems and find general application for the delivery of imaging agents and therapeutics. [11] For cell-labeling studies, we chose an anti-EGFR antibody as our target, as EGFR is of central importance in cancer-cell signaling [12] and therefore a key target for therapeutic inhibition, [13] and because prior studies with fluorophorelabeled antibodies would serve as a reference. [14] Commercially available cetuximab was labeled with trans-cyclooctene succinimidyl carbonate and used for pretargeting experiments. We chose to work with a green fluorescent protein (GFP) positive A549 lung cancer cell line that has been shown to have upregulated levels of EGFR. [15] To label cells pretargeted with trans-cyclooctene-bearing antibodies, the tetrazine amine 1 was conjugated to a commercially available far-red indocyanine fluorophore, Vivo-Tag 680 (VT680 purchased from VisEn Medical). The decision to use tetrazinefluorophore probes was based on the commercial availability of numerous amine-reactive fluorophores. Furthermore, we had used this compound previously and shown that the tetrazine moiety is serum-stable and reacts rapidly with strained dienophiles. [7] Iinitial pretargeting experiments used cetuximab modified by both trans-cyclooctene and a single Alexa Fluor 555 dye (AF555 purchased from Invitrogen). The AF555 dye was conjugated to the antibody in addition to the trans-cyclooctene to track the location of the antibody and determine the specificity of sequential VT680-tetrazine labeling. A549 cancer cells were first incubated with cetuximab-trans-cyclooctene/AF555 (100 nm) for 45 minutes in serum. The cells were then washed, incubated at 37 8C with tetrazine-VT680 (500 nm) for 10 min in 100 % fetal bovine serum (FBS), washed again, and imaged immediately by confocal microscopy ( Figure 2 ). Direct labeling of the antibodies with AF555 was monitored in the red channel (Figure 2 b, red). The antibody was clearly visible both on the surface of the cells and inside the cells as a result of EGFR internalization. [16, 17] Covalently bound tetrazine-VT680 could be visualized clearly in the near-infrared (NIR) channel (Figure 2 c, green). Merging of the red and NIR channels revealed excellent colocalization of the AF555 and VT680 signals with little background fluorescence. This result indicates that the reaction of the tetrazine is extremely selective. As expected, the reaction occurred primarily on the surface of the cells, where EGFR concentrations are highest. A smaller amount of cell-internalized, vesicle-associated NIR fluorescence was Figure 1 . a) Reaction of benzylaminotetrazine 1 with trans-cyclooctenol 2 by an inverse-electron-demand Diels-Alder cycloaddition. Dinitrogen is released, and dihydropyrazine coupling products, such as 3, are formed. b) Live-cell pretargeting. Cancer cells (blue), which overexpress EGFR, are exposed to the cetuximabtrans-cyclooctene conjugate (red). In the next step, the pretargeted cells are labeled with a tetrazine bearing a fluorophore such as VT680 (green). Ü Ü These are not the final page numbers! also observed. This fluorescence is probably a result of EGFR internalization after treatment with tetrazine-VT680. [16, 17] Control experiments with either unlabeled cetuximab and tetrazine-VT680 or trans-cyclooctene-cetuximab and unlabeled VT680 resulted in no NIR fluorescence (see Figure S4 in the Supporting Information). Next, we tested whether labeling could be observed without a washing step to remove the probe. The desire to avoid such a step is relevant to applications in which one is unable to perform stringent and multiple washing steps, such as intracellular labeling, experiments in which cell handling has to be minimized (with rare cells or highly specialized cells), and in vivo labeling. The concentration of the tetrazine-VT680 label was lowered to 50 nm to enable observation of the covalent modification in real time. The images in Figure 3 were taken during continuous imaging of the cycloaddition of the tetrazine-VT680 to the pretargeted trans-cyclooctene on live cancer cells in 100 % FBS. Tetrazine-VT680 first became visible as it reacted and concentrated on the surface of cells; at later times, punctate spots within the cell were visible as tetrazine-labeled cetuximab was internalized.
In an attempt to improve the signal-to-background ratio, we increased the loading density of the reactive transcyclooctene on the targeted antibodies. A greater number of reactive sites per antibody should lead to more fluorophore per antibody after labeling and thus result in signal amplification. To vary the trans-cyclooctene loading, we exposed cetuximab to different molar excesses of the amine-reactive trans-cyclooctene. The conjugates were modified with tetrazine-VT680, and the resulting fluorochrome absorbance was used to estimate the number of reactive trans-cyclooctene units per antibody. In this fashion, cetuximab bearing one, three, five, and six tetrazine-VT680-reactive trans-cyclooctene moieties were prepared. Owing to the large size of indocyanine dyes, for the higher loadings, the number of reactive trans-cyclooctene moieties is probably lower than the actual number of trans-cyclooctene moieties on the antibody. These trans-cyclooctene-cetuximab conjugates bound to EGFR-expressing A549 cells with excellent stability (see Figure S5 in the Supporting Information).
We used flow cytometry to gain a more quantitative understanding of live-cell fluorescent labeling with the tetrazine. A549 cells were incubated with cetuximab (50 nm) modified with either zero, one, three, five, or six reactive trans-cyclooctene units. The cycloaddition was carried out with tetrazine-VT680 (500 nm) at 37 8C in 100 % FBS. After 30 min, the cells were washed, and the fluorescence intensity was analyzed by flow cytometry. Figure 4 a shows the relative VT680 signal intensity after 30 min for all five loadings of the trans-cyclooctene. To illustrate the practical effect of this These are not the final page numbers! Ü Ü amplification on the imaging of live cells, we pretargeted A549 cells with cetuximab (100 nm) conjugated to one, three, five, and six reactive trans-cyclooctene moieties, then exposed the cells to tetrazine-VT680 (100 nm) for 10 min prior to imaging with confocal microscopy (Figure 4 b) . Cells pretargeted with trans-cyclooctene-conjugated cetuximab constructs with higher loadings of the trans-cyclooctene were visualized readily, and the signal diminished as the amount of the dienophile on the antibody decreased. The ability to amplify signals by loading increased amounts of a small molecule on the antibody could provide a strategy for increasing the signal-to-background ratio for in vivo pretargeting schemes.
In conclusion, we have developed a highly sensitive technique for the covalent labeling of live cancer cells on the basis of the cycloaddition of a tetrazine to a highly strained trans-cyclooctene. With the appropriate choice of a cell-permeable labeling agent, this method should be readily extendable to intracellular labeling and could facilitate the tracking of tagged small-molecule drugs, signaling proteins, or other components of the cellular machinery within live cells. Furthermore, it may be possible to incorporate tetrazines and trans-cyclooctene-substituted nonnatural amino acids into proteins of interest in a site-specific manner and then to reveal them in live cells. Given its speed and sensitivity in whole serum, this labeling reaction should be adaptable to in vivo imaging applications. 
Fast and Sensitive Pretargeted Labeling of Cancer Cells through a Tetrazine/trans-Cyclooctene Cycloaddition

Materials and Methods
General materials and methods. All chemicals were purchased from Sigma Aldrich unless noted and were used as received. The amine reactive cyanine dye Vivo-Tag 680 (VT680) and cyanine dye Genhance 680 were purchased from VisEn Medical (Bedford, MA), Alexa Fluor 555 (AF555) was purchased from Invitrogen (Carlsbad, CA), and Dylight 488 was purchased from Thermo Fisher Scientific (Rockford, Il). All solvents were of reagent grade or higher and were used without further purification. Analytical HPLC and LC/MS were performed on a Waters 2695 HPLC equipped with a 2996 diode array detector, a Micromass ZQ4000 ESI-MS module, and a Grace-Vydac RPC18 column (model 218TP5210) at a flow rate of 0.3 mL/min. For all HPLC runs, solvent A consists of water with 0.1% TFA and solvent B is composed of acetonitrile with 10% water and 0.1% TFA. All UV/vis spectra and kinetics experiments were recorded on a Thermoscientific Nanodrop 1000 spectrophotometer. All kinetics data were calculated using Prism 4 for Mac.
Synthetic Methods
Tetrazine amine (1) and tetrazine VT680 were synthesized as previously reported. [1] (Z)-9-Oxabicyclonon-4-ene was purchased from Aldrich and used as received. The synthesis of (Z)-cyclooct-4-enol was performed as previously reported. [2] (E)-cyclooct-4-enol (2) was synthesized from (Z)-cyclooct-4-enol using a modification of a previously reported protocol. [3] Briefly, 1 gram of cyclooctenol (2) and 1.1 g methyl benzoate sensitizer was added to 250 mL solvent (9:1 Ether:Hexanes) in a 500 mL quartz reaction vessel (Southern New England Ultraviolet Company). No attempt to degas the solution was made. The vessel was irradiated with 254 nm light in a Rayonet RPR-100 UV reactor (Southern New England Ultraviolet Company) under constant stirring. At 30 minute intervals, the irradiation was stopped and the entire solution was passed through a column packed with silver nitrate (10%) impregnated silica (commercially available from Aldrich). The solution that passes through was then transferred back into the quartz flask and irradiation was continued. After 6 hours the irradiation was stopped and the silica was added to a solution of ammonium hydroxide and stirred for 5 minutes after which ether was added and stirring continued for 5 more minutes. After stirring the ether phase was decanted, washed with water, dried with magnesium sulfate, and evaporated yielding trans-cyclooctenol (40%) as a mixture of isomers as previously reported. The isomers were separated by column chromatography (1:1 Ethyl Acetate Hexanes) and verified by proton NMR using the previously reported proton NMR spectra. [3] The major isomer (more polar isomer) was used for the synthesis of (4) (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl carbonate (4) . 50 mg of (E)-cyclooct-4-enol (major isomer) and 0.2 mL triethylamine were added to 3 mL anhydrous acetonitrile. To this solution was slowly added 250 mg of N,N!-Disuccinimidyl carbonate. The reaction mixture was stirred at room temperature until thin layer chromatography revealed that the reaction was complete (approximately 48 hours). The acetonitrile was removed by rotary evaporation and the remaining residue was suspended in ether, washed with 0.1M HCl followed by brine, and dried with magnesium sulfate. The ether was evaporated and the resulting oil was purified by column chromatography (1:1 Ethyl Acetate:Hexane) yielding 80 mg (75% yield) of the title compound. 
HPLC Characterization of reaction between tetrazine amine (1) with trans-cyclooctenol (2)
Tetrazine amine (1) and trans-cycloctenol (2) were combined in 100 "L of PBS at a final concentration of 1 mM for each reagent. The solution was agitated for 10 minutes at room temperature and then analyzed by HPLC and LC-MS (Figures S1 and S2) . Multiple peaks were identified with molecular mass corresponding to dihydropyrazine adducts or oxidation products of the adducts. The multiple peaks are expected given the previously demonstrated potential to form several regioisomeric products. [1, 3] The yield of the reaction, based on the remaining signal from the tetrazine amine (1) was greater than 95%. Figure S1 :HPLC trace of purified tetrazine amine (1) using a gradient of 0 to 50 % buffer B over 15 min. Figure S2 : HPLC trace of the reaction products from addition of tetrazine amine (1) to transcyclooctene (2) . All peaks gave mass identities corresponding to dihydropyrazine adducts.
Labeling Antibody with trans-cyclooctene Cetuximab (ImClone 2 mg/mL) was purchased and the solvent exchanged for 0.1M NaHCO3 buffered at pH 8.5 with a final concentration of 7 mg/mL. To 200 !L of this stock solution was added 10 !L of DMF. (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl carbonate was dissolved in anhydrous DMF to make a 40 mM stock solution. For conjugation, the appropriate excess of amine reactive trans-cyclooctene in DMF was aliquoted into the antibody solution, vortexed, and reacted overnight at 4 o C. In the experiments reported, the final trans-cycloctene loadings of 1, 3, 5, and 6 correspond to using 2, 10, 30, and 100 equivalents of succinimidyl carbonate with respect to antibody. After overnight reaction the antibodies were purified by centrifuge filtration using 5% DMSO PBS, concentrated to 2 mg/mL and stored in PBS at 4 o C.
Antibody Labeling with Fluorescent Succinimidyl Esters
A solution of antibody (1 mg/mL) in 0.1M NaHCO3 (pH 8.5) was incubated with 2 equivalents of fluorescent succinimidyl ester (VT680, AF555, or Dylight 488) for 2 hours. After incubation, the antibody was purified by centrifuge filtration using 30000 dalton molecular weight cutoff filters (Amicon) and stored in PBS. The number of fluorochromes per antibody was determined by spectrophotometric analysis and determined to be approximately 1 per antibody for all dye succinimidyl esters used.
Kinetic Measurements
trans-cyclooctene modified antibody was physically absorbed onto polystyrene by immersing the surfaces in a 0.1 mg/mL solution of antibody in PBS for 3 hours. After numerous washes with PBS, the surface was exposed to 750 nM tetrazine VT680 in PBS at 37 o C. After 5 minutes, the tetrazine solution was removed and the surface washed 3 times with PBS. The fluorescence due to the VT680 dye was measured on a fluorescence plate reader (Tecan Safire 2) and corrected for background fluorescence. The surface was again exposed to the tetrazine solution and the entire process repeated at 10, 15, 30, and 60 minutes. The fluorescence measurements were plotted versus time, fitted to a first order exponential growth curve and the pseudo first order rate constant determined ( Figure S3 Left) . The entire experiment was repeated using two different concentrations of tetrazine (375 nM and 1000 nM) and the pseudo first order rate constants from all three experiments were plotted versus concentration, fitted to a straight line, and the slope taken as the second order rate constant. reported at the second order rate constant for the reaction between tetrazine VT680 and trans-cyclooctene bound to antibody.
Cell Culture
The human lung adenocarcinoma epithelial cell line A549 was selected for all experiments due to its mid-level over-expression of EGFR. The cell line was maintained in a standard ATCC formulated F-12K media supplemented with 10% fetal bovine serum and 5% penicillin/streptomycin. In order to facilitate microscopy and visualize intracellular morphology, EGFP labeling of the cell line was done using a third-generation lentiviral vector system. 293T cells were transfected using lipofectamine 2000 in a subconfluent 10-cm dish with the vector pCCLsin.PPT.hPGK (10 !g), into which EGFP had been cloned, as well as pMDLg/p packaging (7 !g) and VSV-G envelope encoding pMD.G (5 !g) plasmids. These plasmids were obtained from Rafaella Sordella at the MGH Center for Cancer Research and Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy. Viral supernatant was collected after 48 hours, filtered with a 0.45 micron syringe filter, and stored at -80°C. The A549 cell line was infected in subconfluent wells of 24-well plates, using 300 !L of virus in 1 mL of F-12K culture media with 10% fetal calf serum. This protocol yielded an infection rate in excess of 80% (determined by visual assessment using fluorescence microscopy). EGFP-negative cells were removed using a modified 5-laser Becton-Dickinson FACSDiVa with standard techniques.
Confocal Microscopy
Cells were grown on break away glass chamber slides and washed six times after administering either imaging agent. A multichannel upright laser-scanning confocal microscope (FV1000; Olympus) was used to image live cells with a 60X water immersion objective lens. Image collection and fluorophore excitations with lasers at 488nm (EGFP), 543nm (AF555), and 633nm (VT680) were done serially to avoid cross talk between channels. Data were acquired with Fluoview software (version 4.3; Olympus) and image stacks were processed and analyzed with ImageJ software (version 1.41, Bethesda MD).
Flow cytometry
Confluent A549 cells were suspended using 0.05% Tryspin/0.53 mM EDTA, washed by centrifugation with PBS containing 2% FBS (PBS+), and 2.5x10 5 cells were added to microcentrifuge tubes. Cetuximab antibody with the following modifications was then added at 10 !g/ml concentration in 100 !L PBS+: none (control), 1 trans-cyclooctene per antibody, 3 trans-cyclooctene per antibody, 5 trans-cyclooctene per antibody, 6 trans-cyclooctene per antibody. Following incubation for 15 minutes at room temperature, samples were washed with PBS+. For stability studies, trans-cyclooctene antibodies were labeled with Dylight 488 fluorophore (Pierce, ~1 per antibody) and the cells were resuspended in 100 !L PBS+ and incubated for 15, 30, or 60 minutes at 37ºC before addition of 1 ml PBS+ and 2 washes by centrifugation. For clicking studies, labeled cells were resuspended in 100 !L FBS containing 500 nM tetrazine-VT680 and incubated for 30 minutes at 37ºC before addition of 1 ml PBS+ and 2 washes by centrifugation. VT680 and DyeLight-488 fluorescence was assessed using an LSRII flow cytometer (Becton Dickinson) and analyzed using FlowJo software. Figure S4 : Confocal microscopy of GFP-positive A549 lung cancer cells after control labelings. Cells were exposed to unlabeled Cetuximab antibody, washed, exposed to tetrazine-VT680 probe (500 nM 10 minutes 100% FBS 37 Figure S5 : Stability study of Dylight 488 Cetuximab modified with either 1 (blue), 3 (green), 5 (yellow), or 6 (red) reactive trans-cyclooctene. A549 cells were exposed to antibody, washed, and the fluorescence intensity monitored with time using flow cytometry.
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